These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Comparison of the susceptibility of falciparum malaria to mefloquine-sulphadoxine-pyrimethamine and chloroquine in Nigeria.
    Author: Fadeke Aderounmu A, Salako LA, Laoye AJ, Modupe Makinde J, Aina Adio R.
    Journal: Afr J Med Med Sci; 1988 Dec; 17(4):195-200. PubMed ID: 2854365.
    Abstract:
    In Nigeria chloroquine remains the drug of choice for the treatment of falciparum malaria since chloroquine resistance is not yet a problem. Nevertheless, in view of the rapid spread of multi-resistant Plasmodium falciparum in Africa, it is desirable to test alternative drugs for efficacy and safety. To this end we undertook a comparative controlled trial of the new triple combination, mefloquine-sulphadoxine-pyrimethamine (MSP, Fansimef, Hoffman-La Roche, Switzerland) with chloroquine in a group of Nigerian children with symptomatic falciparum malaria. Our results showed that Fansimef was a rapidly acting blood schizontocide against the Nigerian strain of P. falciparum, and was well tolerated. In particular, sinus bradycardia, which was frequently observed with Fansimef in the trials conducted in Zambia, was not seen in any of the Nigerian patients.
    [Abstract] [Full Text] [Related] [New Search]